Neimeth International Pharmaceuticals Plc recorded a modest 9 percent year-on-year rise in profit after tax to N339.77 million for the nine months ended September 2025, despite a steep increase in finance costs that weighed on operating margins.
The drugmaker’s profit after tax was supported by
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
